Cargando…
Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor. However, the approval of checkpoint blockade immunotherapy has shifted the treatment paradigm and provides hope for improved survival. The ability of non-small-cell lung cancer (NSCLC) to evade t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342609/ https://www.ncbi.nlm.nih.gov/pubmed/28293123 http://dx.doi.org/10.2147/LCTT.S105678 |